Fusion protein comprising bacteriophage λ GpD fused to a GP2 antigen derived from HER-2/neu
AssigneeTheraphage Inc.
InventorsRoderick A. Slavcev, Javad Behravan
Life of this patent
Estimating the term…
Abstract
Described herein is a fusion protein comprising a bacteriophage protein fused to a cancer antigen. Vaccines are also described, as well as methods of treatment and/or prevention of cancer and methods of immunizing an individual.
Claims17
A fusion protein comprising bacteriophage λ gpD fused to a GP2 antigen derived from HER-2/neu and a linker linking the gpD and the GP2 antigen, wherein the linker comprises a GG repeat, a GS repeat, or a combination thereof.
A method for treating cancer in a subject in need thereof, comprising administering to the subject a fusion protein comprising bacteriophage λ gpD fused to a GP2 antigen derived from HER-2/neu and a linker linking the gpD and the GP2 antigen, wherein the linker comprises a GG repeat, a GS repeat, or a combination thereof.
Dependencies are inferred from the claim text.